![Marcella Ruddy](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Marcella Ruddy
Director/Board Member at POLAREAN IMAGING PLC
Net worth: 571 761 $ as of 30/05/2024
Marcella Ruddy active positions
Companies | Position | Start | End |
---|---|---|---|
POLAREAN IMAGING PLC | Director/Board Member | 25/08/2022 | - |
Tectonic Therapeutic, Inc.
![]() Tectonic Therapeutic, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tectonic Therapeutic, Inc., Tectonic Operating Co., Inc. is a company that is transforming the discovery of antibodies and other biologic drugs targeting G-protein coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. The company is based in Watertown, MA. With its proprietary Geode™ platform, Tectonic aims to unlock the therapeutic utility of some of the most difficult receptors in the class. The company was founded by Andrew Kruse and Timothy A. Springer. Alise S. Reicin has been the CEO of the company since 2020. Tectonic Operating Co. was acquired by AVROBIO, Inc. on June 20, 2024 for $7.56 million. | Chief Tech/Sci/R&D Officer | 30/06/2021 | - |
MKRuddy Consulting LLC | Director/Board Member | - | - |
Upstream Bio, Inc.
![]() Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | Director/Board Member | 06/02/2023 | - |
Career history of Marcella Ruddy
Former positions of Marcella Ruddy
Companies | Position | Start | End |
---|---|---|---|
TECTONIC THERAPEUTIC, INC. | Chief Tech/Sci/R&D Officer | 19/06/2024 | - |
Training of Marcella Ruddy
Washington University in St. Louis | Doctorate Degree |
Princeton University | Undergraduate Degree |
Statistics
International
United States | 7 |
United Kingdom | 2 |
Operational
Director/Board Member | 3 |
Chief Tech/Sci/R&D Officer | 3 |
Doctorate Degree | 1 |
Sectoral
Health Technology | 3 |
Commercial Services | 3 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
POLAREAN IMAGING PLC | Health Technology |
Private companies | 4 |
---|---|
Tectonic Therapeutic, Inc.
![]() Tectonic Therapeutic, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tectonic Therapeutic, Inc., Tectonic Operating Co., Inc. is a company that is transforming the discovery of antibodies and other biologic drugs targeting G-protein coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. The company is based in Watertown, MA. With its proprietary Geode™ platform, Tectonic aims to unlock the therapeutic utility of some of the most difficult receptors in the class. The company was founded by Andrew Kruse and Timothy A. Springer. Alise S. Reicin has been the CEO of the company since 2020. Tectonic Operating Co. was acquired by AVROBIO, Inc. on June 20, 2024 for $7.56 million. | Commercial Services |
MKRuddy Consulting LLC | |
Upstream Bio, Inc.
![]() Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | Commercial Services |
Avrobio, Inc.
![]() Avrobio, Inc. BiotechnologyHealth Technology AVROBIO, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Watertown, MA. | Health Technology |
- Stock Market
- Insiders
- Marcella Ruddy
- Experience